Revolutionizing Cancer Treatment – Phio Pharmaceuticals Corp. is pioneering RNA-based immunotherapies. Don’t miss their virtual non-deal roadshow for key insights into their pipeline and strategy. #RenmarkVNDR Registration: https://ow.ly/wEvi50VavxU #PHIO #biotech #INTASYL #gene #silencing #treatment
Phio Pharmaceuticals Corp.
生物技术研究
Marlborough，Massachusetts 1,787 位关注者
Phio’s proprietary RNA interference (RNAi) technology makes immune cells more effective in killing tumor cells.
关于我们
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL? RNAi technology makes immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems. Phio was co-founded by Nobel Laureate Craig Mello, who was awarded the Nobel prize in 2006 for his discovery of RNAi, which has broad therapeutic applications. Our founders opened up a whole new field of biology when they discovered RNAi, and we continue their pioneering efforts today through our work with INTASYL. We’re committed to discovering and developing innovative cancer treatments for patients, creating new pathways for a cancer-free future. For additional information, visit the Company's website, www.phiopharma.com. #INTASYL #siRNA #RNAi #Phio #immunooncology
- 网站
-
https://www.phiopharma.com
Phio Pharmaceuticals Corp.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Marlborough，Massachusetts
- 类型
- 上市公司
- 创立
- 2012
地点
-
主要
获取路线
257 Simarano Dr
US，Massachusetts，Marlborough，01752
Phio Pharmaceuticals Corp.员工
动态
-
Phio Pharmaceuticals’ CEO Bob Bitterman will present at the Renmark Financial Communications Virtual Non-Deal Roadshow on Tuesday February 4 at 2:00 PM EST. Please join us to learn more about Phio’s proprietary INTASYL siRNA technology and its on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Register here: https://lnkd.in/eS68yez9 Note: If the link does not work, please copy and paste into your browser. To ensure smooth connectivity, please access the link above using the latest version of Google Chrome. For additional information, visit the Company's website, www.phiopharma.com.
-
Don’t miss the Jan 29 Virtual Non-Deal Roadshow featuring Phio Pharmaceuticals’ CEO Robert Bitterman. Mr. Bitterman will be discussing Phio’s proprietary INTASYL siRNA technology and its on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Phio's presentation and live Q&A is hosted by Renmark Financial Communications Inc. REGISTER HERE: Renmark Virtual Non-Deal Roadshow: NASDAQ - PHIO | Event Registration | Renmark Financial Communications If the link does not work, please copy and paste into your browser. Also to ensure smooth connectivity, access the link above using the latest version of Google Chrome. And, if you miss the event, a replay may be accessed on the Renmark Financial Communications Inc. website at https://lnkd.in/dzGBHUa9
-
We are honored to be nominated as one of the finalist for the Tech Disruptor of the Year Award at the 2025 Advanced Therapies Week organized by Phacilitate. ???The 2025 Advanced Therapies Awards Shortlist Is Here!??? Winners will be announced at the prestigious?Advanced Therapies Awards at?Union Station Wolfgang Puck on Wednesday, January 22. Let’s celebrate the leaders shaping the future of advanced therapies! ?? #ATA25 hashtag #Innovation hashtag #CellandGeneTherapy hashtag #RegenerativeMedicine hashtag #Leadership Uniphar Group Cryoport Systems Catalent Pharma Solutions Marken OrganaBio Resilience CoJourney Akadeum Life Sciences, Inc. BioLife Solutions, Inc. Partners4Access Cellular Origins Phio Pharmaceuticals Corp. Cellares EVast Bio Inc. VIVEbiotech Forge Biologics Pluri SK pharmteco Kudo Biotechnology Nanoscope Therapeutics Inc. Exothera Charles River Laboratories Group IASO BioRestorative Therapies, Inc. Poseida Therapeutics, Inc. AviadoBio INCELL Corporation GC Cell Siren Biotechnology NKILT Therapeutics, Inc. KOMO BIOSCIENCES Orchestra Life Sciences BlueWhale Bio The Medicine Maker Foundation for Angelman Syndrome Therapeutics
-
Phio is a finalist for the Technology Disruptor of the Year for its INTASYL? technology, and the winner will be announced next week at Advanced Therapies Week 2025, a cell and gene conference. INTASYL is the technology behind the company’s recent positive news about its Phase 1b clinical trial—two of the patients in the 2nd cohort had 100% tumor clearance at Day 36, one patient had 90% tumor clearance and one patient had stable disease, having not progressed. According to the conference organizers, the Technology Disruptor Award “celebrates exceptional contributions to the field of cell and gene therapy through technological innovation. It is awarded to organizations and individuals who have significantly advanced their industry by effectively successfully implementing and utilizing new technologies.” #Phio #INTASYL?#RNAi?#siRNA?#Immunooncology?
-
Phio is a finalist for the Technology Disruptor of the Year for its INTASYL? technology, and the winner will be announced next week at Advanced Therapies Week 2025, a cell and gene conference. INTASYL is the technology behind the company’s recent positive news about its Phase 1b clinical trial—two of the patients in the 2nd cohort had 100% tumor clearance at Day 36, one patient had 90% tumor clearance and one patient had stable disease, having not progressed. According to the conference organizers, the Technology Disruptor Award “celebrates exceptional contributions to the field of cell and gene therapy through technological innovation. It is awarded to organizations and individuals who have significantly advanced their industry by effectively successfully implementing and utilizing new technologies.” #Phio #INTASYL?#RNAi?#siRNA?#Immunooncology?
-
Phio's 2nd cohort clinical trial results include 2 patients with 100% tumor clearance and one with 90% tumor clearance. Learn more: www.phiopharma.com #Phio #RNAi #immunooncology #siRNA #skincancer